Company insight
Pure, proven and stable Vitamin K2
A standout K2 product, which earns customer loyalty, starts with the purity of the raw material and the clinical validation that it delivers health benefits. Gnosis by Lesaffre is the partner that guarantees those opportunities.
V
itamin K2 is experiencing an impressive surge in the market, and global awareness of its
importance for bone and cardiovascular health is at an all-time high. According to the Industry Transparency Center’s 2022 Supplement Consumer Survey, of the 3,500 participants from the US, China, UK, Germany, and Italy, 62% reported using K2 supplements, with bone health and heart health ranking as the top reasons. “Perceived effectiveness” of K2 was greater in total supplement users surveyed than regular users, suggesting that future growth is likely as new consumers discover Vitamin K2. And the top five reasons consumers seek out branded ingredients, including Vitamin K2, were quality, safety, trust, efficacy and clinical validation. This recognition stems from brand owners investing in high-quality, clinically proven Vitamin K2 raw materials. Therefore, manufacturers actively partner with Gnosis by Lesaffre, the global K2 expert offering the only clinically validated K2 as MK-7 on the market: MenaQ7.
Focus on purity True innovation is imperative for the supplements industry, which must start with the quality raw materials supplied to the market. Purity is of utmost concern for ingredients – not just in delivering an ‘active’ material but ensuring high quality too. Producing Vitamin K2 as MK-7 requires expertise of the K2 molecule to ensure it is appropriately handled, so its natural, bioactive all-trans form is delivered to the natural products industry. By selecting the right industry partner, brands can be confident that their K2 ingredient is the active form that provides the health benefits consumers expect based on label claims.
Stability drives innovation Brand owners want to create the most standout products on the market, which means exploring unique synergistic ingredient combinations that deliver more health benefits in a single product. In December 2021, Gnosis by Lesaffre introduced a proprietary technology called Matrix, which offers protection of Vitamin
K2 in any formulation, especially those utilising complex minerals, streamlining the formulation process while ensuring stability. With Matrix, developed explicitly for vitamin K2, formulators do not need to add additional ingredients for the protective technology. Matrix comes with no coating, no additive, and no other ingredient; it offers the shortest list of ingredients, limited to the active molecule and a carrier.
Synergistic mechanism Vitamin K2’s recognition as an essential bone- and heart-health ingredient comes from its mechanism of action being clinically validated with MenaQ7 K2 as MK-7. To that end, all industry claims for K2 come from MenaQ7 science.
Even more, those studies have confirmed K2 as the perfect complement for other well- recognised ingredients on the market that carry their own approved health claims: ■ Vitamin D3: Known for immune support, Vitamin D3 in combination with MenaQ7 K2 is clinically shown to synergistically deliver cardiovascular benefits, compared with D3 alone, and promotes bone mineral density in children.
■ Omega-3s: An essential healthy ageing ingredient, especially for early childhood development, Omega-3 is also well-known for cardiovascular support. However, MenaQ7 delivers the one area of heart health that Omega-3s lack: promoting arterial flexibility. These two ingredients create the most impactful cardio-support products, while K2 also enables a bone health-support claim.
Gnosis by Lesaffre continues to drive innovation and clinical validation and provide K2 as MK-7 for essential studies. ●
The surge the Vitamin K2 category is experiencing stems from manufacturers demanding pure, clinically proven ingredients that deliver on the promise of better health.
Ingredients Insight /
www.ingredients-insight.com
www.gnosisbylesaffre.com 25
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84
